Capital DailyCapital Daily
Markets · Investing · Business
Capital DailyCapital Daily
Finance

Which iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB?

IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the volatility and a 1.5% dividend yield.

Which iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB?

Published July 23, 2026 · Category: Finance

Overview

Choosing between iShares Global Healthcare ETF (NYSEMKT:IXJ) and iShares Biotechnology ETF (NASDAQ:IBB) involves a trade-off between broad healthcare stability and the high-growth, high-volatility nature of biotechnology.

For investors seeking to navigate the healthcare sector, understanding whether to prioritize broad-market stability or sub-sector growth is essential for portfolio construction. While both utilize a passive strategy, their underlying benchmarks result in different experiences regarding price swings and income potential for long-term holders.

Details

Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.

Continue reading

Source

Originally published at www.fool.com.

Related Articles

CD
Capital Daily Newsroom

Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.